請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66684
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王萬波 | |
dc.contributor.author | Shu-Ping Hsueh | en |
dc.contributor.author | 薛淑萍 | zh_TW |
dc.date.accessioned | 2021-06-17T00:51:06Z | - |
dc.date.available | 2017-03-02 | |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-11-16 | |
dc.identifier.citation | References
1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12. 2. Tyson FL, Boyer CM, Kaufman R, et al. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 1991; 165: 640-6. 3. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195-217. 4. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999; 274: 8865-74. 5. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-13. 6. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18: 2149-64. 7. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-84. 8. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6986-96. 9. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994; 54: 3260-6. 10. Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901. 11. Lin YC, Peng JM, Wang WB. The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Oncogene 2000; 19: 2704-13. 12. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-71. 13. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000; 6: 250-9. 14. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-4. 15. Hung MC, Schechter AL, Chevray PY, Stern DF, Weinberg RA. Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci U S A 1986; 83: 261-4. 16. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9. 17. Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 1985; 82: 6497-501. 18. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-30. 19. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-4. 20. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-55. 21. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006; 12: 6326-30. 22. Kiyokawa N, Karunagaran D, Lee EK, Xie Y, Yan DH, Hung MC. Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu. Oncogene 1997; 15: 2633-41. 23. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003; 30: 38-48. 24. Marti U, Burwen SJ, Wells A, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991; 13: 15-20. 25. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-8. 26. Xie Y, Hung MC. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 1994; 203: 1589-98. 27. Wang SC, Lien HC, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004; 6: 251-61. 28. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002; 157: 929-39. 29. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294: 2179-81. 30. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003; 2: 179-91. 31. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-45. 32. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277: 18649-57. 33. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-5. 34. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-12. 35. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-47. 36. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13: 1359-65. 37. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605. 38. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56. 39. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995; 75: 2147-52. 40. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998; 17: 61-5. 41. Lee S, Yang W, Lan KH, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002; 62: 5703-10. 42. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31. 43. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17: 2235-49. 44. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002; 8: 475-86. 45. Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther 2001; 8: 728-39. 46. Zhang L, Hung MC. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996; 12: 571-6. 47. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997; 15: 953-60. 48. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38. 49. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-12. 50. Ali S, Metzger D, Bornert JM, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. Embo J 1993; 12: 1153-60. 51. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-35. 52. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37. 53. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54. 54. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24: 85-95. 55. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-46. 56. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995; 34: 97-117. 57. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81: 137-44. 58. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-35. 59. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998; 1377: M25-37. 60. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994; 9: 3601-8. 61. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491-4. 62. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 1996; 15: 2174-83. 63. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94. 64. Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H, Colomer R. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004; 86: 125-37. 65. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003; 2: 1113-20. 66. Guo G, Wang T, Gao Q, et al. Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene 2004; 23: 535-45. 67. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-9. 68. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44. 69. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48. 70. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002; 9: 75-85. 71. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. 72. Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002; 29: 59-65. 73. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-90. 74. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232: 123-38. 75. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-47. 76. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-37. 77. Takai N, Jain A, Kawamata N, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005; 104: 2701-8. 78. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68. 79. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24: 4324-32. 80. Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13: 6175-81. 81. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20. 82. Fisk B, Hudson JM, Kavanagh J, et al. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 1997; 17: 45-53. 83. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993; 151: 225-34. 84. Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 1994; 157: 415-27. 85. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-8. 86. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-32. 87. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289-97. 88. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-17. 89. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8: 1014-8. 90. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995; 92: 432-6. 91. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999; 5: 1884-91. 92. Zhang L, Chang CJ, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 1995; 55: 3890-6. 93. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 1999; 5: 343-53. 94. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31 Pt 2: 2332-48. 95. Wright M, Grim J, Deshane J, et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 1997; 4: 317-22. 96. Neve RM, Sutterluty H, Pullen N, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000; 19: 1647-56. 97. Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 1996; 3: 89-98. 98. De Lorenzo C, Arciello A, Cozzolino R, et al. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 2004; 64: 4870-4. 99. De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D'Alessio G. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 2007; 581: 296-300. 100. Suen TC, Hung MC. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol Cell Biol 1991; 11: 354-62. 101. Mizuguchi G, Kanei-Ishii C, Takahashi T, et al. c-Myb repression of c-erbB-2 transcription by direct binding to the c-erbB-2 promoter. J Biol Chem 1995; 270: 9384-9. 102. Xing X, Wang SC, Xia W, et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000; 6: 189-95. 103. Matin A, Hung MC. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ 1993; 4: 1051-6. 104. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 1990; 87: 4499-503. 105. Chuang TC, Way TD, Lin YS, Lee YC, Law SL, Kao MC. The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett 2002; 532: 135-42. 106. Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002; 62: 6712-6. 107. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 1998; 17: 2167-75. 108. Shao R, Karunagaran D, Zhou BP, et al. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 1997; 272: 32739-42. 109. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422-33. 110. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7: 1237-45. 111. Villaret D, Glisson B, Kenady D, et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002; 24: 661-9. 112. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8. 113. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108: 71-7. 114. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr., Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279: 4339-45. 115. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97. 116. Humphreys DT, Westman BJ, Martin DI, Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A 2005; 102: 16961-6. 117. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-86. 118. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009; 284: 24696-704. 119. Roh H, Pippin J, Drebin JA. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 2000; 60: 560-5. 120. Roh H, Pippin JA, Green DW, et al. HER2/neu antisense targeting of human breast carcinoma. Oncogene 2000; 19: 6138-43. 121. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery 1999; 126: 413-21. 122. Kashani-Sabet M, Scanlon KJ. Application of ribozymes to cancer gene therapy. Cancer Gene Ther 1995; 2: 213-23. 123. Czubayko F, Downing SG, Hsieh SS, et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther 1997; 4: 943-9. 124. Suzuki T, Anderegg B, Ohkawa T, et al. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther 2000; 7: 241-8. 125. Lui VW, He Y, Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol Ther 2001; 3: 169-77. 126. He P, Zhu D, Hu JJ, Peng J, Chen LS, Lu GX. pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth. Mol Biol Rep; 37: 1597-604. 127. Aigner A, Hsieh SS, Malerczyk C, Czubayko F. Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology 2000; 144: 221-8. 128. Abuharbeid S, Apel J, Sander M, et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 2004; 321: 403-12. 129. Pandya NM, Dhalla NS, Santani DD. Angiogenesis--a new target for future therapy. Vascul Pharmacol 2006; 44: 265-74. 130. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997; 78: 672-7. 131. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-79. 132. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8. 133. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-5. 134. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-12. 135. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-65. 136. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39. 137. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-20. 138. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8. 139. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6: 373-8. 140. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5. 141. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994; 71: 374-9. 142. Kimura H, Weisz A, Ogura T, et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001; 276: 2292-8. 143. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000; 19: 597-614. 144. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-8. 145. Sargiannidou I, Zhou J, Tuszynski GP. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 2001; 226: 726-33. 146. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-17. 147. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765: 178-88. 148. Bouck N. P53 and angiogenesis. Biochim Biophys Acta 1996; 1287: 63-6. 149. Chen QR, Mixson AJ. Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. Front Biosci 1998; 3: D997-D1004. 150. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4. 151. Laderoute KR, Alarcon RM, Brody MD, et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 2000; 6: 2941-50. 152. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004; 286: F278-87. 153. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-31. 154. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-9. 155. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30. 156. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855-61. 157. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84. 158. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008; 29: 704-12. 159. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004. 160. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 2005; 65: 3257-63. 161. Yen L, Benlimame N, Nie ZR, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002; 13: 4029-44. 162. Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66: 2028-37. 163. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-60. 164. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007; 43: 1117-24. 165. Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007; 67: 1487-93. 166. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80. 167. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57: 1199-205. 168. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell; 141: 52-67. 169. Urban P, Vuaroqueaux V, Labuhn M, et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 2006; 24: 4245-53. 170. Beckers J, Herrmann F, Rieger S, et al. Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis. Int J Cancer 2005; 114: 590-7. 171. Girardi AJ, Sweet BH, Slotnick VB, Hil | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66684 | - |
dc.description.abstract | HER2 致癌基因在許多人類癌細胞 (特別是卵巢癌和乳癌) 中有大量表現的情形。研究發現HER2會促進癌細胞生長、存活、血管新生 (angiogenesis)、癌細胞轉移 (metastasis)、抑制癌細胞對化療藥物的感受性 (chemosensitivity) 和降低生命存活率,若在HER2大量表現的癌細胞中抑制HER2的表現則會降低癌細胞生長、存活、血管新生、增加癌細胞對化療藥物感受性和增加生命存活率。我們先前證明了猴病毒四十型(SV40)的T/t-common polypeptide在HER2大量表現的癌細胞會透過抑制HER2的表現進而抑制癌細胞形成腫瘤的能力,此外也可使HER2大量表現的人類卵巢癌和乳癌細胞進行細胞凋亡(apoptosis)。本論文第一部分探討T/t-common在具有HER2大量表現的人類卵巢癌細胞SK-OV-3中是否會抑制血管新生。利用具有T/t-common 表現的SK-OV-3 細胞培養液(conditioned medium) 發現會抑制內皮細胞的移動 (migration)、血管生成 (tube formation) 和動物體內血管生成 (microvessel formation),證明了T/t-common 可抑制SK-OV-3誘發血管新生的能力。若將HER2基因重新送入可表現T/t-common的SK-OV-3細胞 (T/t-common stable clones)中並使HER2再大量表現;收集細胞培養液進行實驗,發現HER2會降低T/t-common抑制內皮細胞移動和血管生成的能力,因此T/t-common抑制血管新生能力是透過抑制了HER2的表現。T/t-common在SK-OV-3中會抑制一些血管新生因子 (proangiogenic factors) 例如(VEGF-A、IL-8、bFGF、uPA、MMP-2)的表現和促進一些抑制血管新生因子 (antiangiogenic factors) 例如(TSP-1、TIMP-1)的表現。我們也進一步証明T/t-common在SK-OV-3中是透過抑制 ERK1/2活性進而抑制轉錄因子HIF-1α 和血管新生因子VEGF-A的表現,此外T/t-common可促進p38活性進而增加抗血管新生因子TSP-1的表現,因此T/t-common可透過HER2-ERK1/2-HIF-1α-VEGF-A和HER2-p38-TSP-1訊息傳遞路徑來抑制HER2誘發血管新生能力。將HER2大量表現的卵巢癌細胞SK-OV-3種植在免疫缺陷老鼠NOD/SCID並以T/t-common治療,發現T/t-common在NOD/SCID老鼠可抑制HER2大量表現腫瘤的血管新生和腫瘤生長。因此利用T/t-common做基因治療可能是一種治療HER2大量表現癌症的新方法。
本論文第二部份則探討T/t-common在具抗藥性的HER2大量表現的癌細胞中,是否能增強癌細胞對化療藥物cisplatin (CDDP)及doxorubicin (DXR)的感受性,並進一步探討其增強化療藥物療效的機制。結果顯示T/t-common可特異性地加強CDDP或DXR 對HER2大量表現癌細胞的毒殺能力,並經由增加Caspase 3的活性誘發癌細胞進行細胞凋亡而增加化療藥物療效。當HER2大量表現的癌細胞同時以T/t-common 和CDDP或DXR作用下,發現T/t-common可抑制ERK1/2的活性和促進JNK的活性,並藉此抑制Bcl-2和Bcl-XL的表現,因此T/t-common可能是經由調控上述細胞凋亡因子進而增強CDDP或DXR誘發HER2大量表現癌細胞細胞凋亡。最後將HER2大量表現的卵巢癌細胞SK-OV-3.ip1植入免疫缺陷老鼠NOD/SCID,並以T/t-common和化療藥物DXR一同治療,發現腫瘤體積比任一單獨試劑治療還小。因為T/t-common可增強CDDP或DXR毒殺HER2大量表現癌細胞的能力,所以T/t-common與CDDP或DXR的合同療法也許可克服HER2大量表現癌細胞對化療藥物的抗藥性,因此是一種具有潛力的治療HER2大量表現癌細胞的新方法。 | zh_TW |
dc.description.abstract | Overexpression of HER2 has been frequently detected in many types of human cancer, most notably breast and ovarian cancers. HER2 overexpression is associated with increased angiogenesis, increased metastasis, increased chemoresistance and reduced survival. Inhibition of HER2 in HER2-overexpressing cancers can lead to reduced angiogenesis, reduced chemoresistance and improved survival. Previously, we reported that Simian Virus 40 T/t-common polypeptide can inhibit HER2, suppress the tumorigenic potential of HER2-overexpressing cancer cells and specifically induce apoptosis in HER2-overexpressing human cancer cell lines. In the part I of this thesis, we further explored the effect of T/t-common on tumor angiogenesis. We found that T/t-common could inhibit the ability of HER2-overexpressing cancer cells, but not low HER2-expressing cancer cells, to induce the migration and tube formation of endothelial cells. Reexpression of HER2 could block T/t-common’s activity to inhibit the ability of HER2-overexpressing cancer cells to induce the migration and tube formation of endothelial cells. We further tested whether T/t-common could affect HER2-overexpressing cancer cells to express and secrete angiogenic and anti-angiogenic factors. We found that T/t-common could inhibit the expression of proangiogenic factor VEGF-A, IL-8, bFGF, uPA and MMP-2, and induce the expression of anti-angiogenic factor TSP-1and TIMP-1 in HER2-overexpressing human SK-OV-3 ovarian cancer cells. T/t-common was found to be able to repress the expression of HIF-1α, a transcription factor required for VEGF-A expression, through inhibiting HER2-mediated ERK1/2 activity. Moreover, T/t-common was found to be able to activate p38 pathway, leading to up-regulation of TSP-1. Through regulating HER2-ERK1/2-HIF-1α-VEGF-A and HER2-p38-TSP-1 signaling pathways in HER2-overexpressing cancer cells, T/t-common could inhibit these cancer cells to recruit endothelial cells, leading to inhibition of angiogenesis in HER2-overexpressing tumors. Two experiments described below demonstrated that T/t-common indeed can inhibit tumor angiogenesis. First, in Matrigel plug assays, we demonstrated that conditioned medium from T/t-common-transduced SK-OV-3 cancer cells had lower ability to induce blood vessel formation in Matrigel plugs than that from control SK-OV-3 cells. Second, infection of adenovirus carrying T/t-common gene could lead to inhibition of the growth and microvessel formation of SK-OV-3 tumors in NOD/SCID mice model. Taken together, the above suggest that T/t-common had the potential to be developed as a new antiangiogenic agent specific for treating HER2-overexpressing ovarian cancers.
In the part II of this thesis, we investigated whether T/t-common could enhance the sensitivity of HER2-overexpressing human cancer cells to chemotherapeutic agents such as cisplatin (CDDP) and doxorubicin (DXR). We found that T/t-common could specifically enhance the sensitivity of HER2-overexpressing human cancer cells, but not that of HER2 low-expressing human cancer cells, to CDDP and DXR. T/t-common could specifically enhance CDDP- or DXR-induced apoptosis by activating caspase-3 activity in HER2-overexpressing cancer cells. T/t-common expression led to down-regulation of Bcl-2 and Bcl-XL, inhibition of ERK activity, and activation of JNK activity in CDDP- or DXR-treated HER2-overexpressing BT-474 cancer cells. This modulation of apoptosis regulatory molecules by T/t-common may contribute to its ability to enhance CDDP- or DXR-induced apoptosis in HER2-overexpressing cancer cells. Finally, we showed that T/t-common could enhance the antitumor activity of DXR on HER2-overexpressing SK-OV-3.ip1 tumor in NOD/SCID mice. Together, these data demonstrated that T/t-common could sensitize HER2-overexpressing cancer cells to chemotherapeutic agents CDDP or DXR, and suggest that combination therapy using T/t-common gene and chemotherapeutic agents (such as CDDP or DXR) may overcome tumor chemoresistance and thus provide a new approach for treatment of HER2-overexpressing cancers. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:51:06Z (GMT). No. of bitstreams: 1 ntu-100-D92445008-1.pdf: 5845097 bytes, checksum: bf0fa173f30488cf5e342caaa121a300 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要……………………………………………………………………… i
Abstract…………………………………………………………………………. iii Contents………………………………………………………………………… vi Chapter 1. Induction………………………………………………………… 1 1.1 HER2……………………………………………………………………. 1 1.2 Overexpression of HER2 and resistance to conventional therapies… 3 1.3 Strategies to target HER2 overexpression……………………………. 6 1.4 Angiogenesis……………………………………………………………. 13 1.4.1 HER2 regulates angiogenesis………………………………………….. 15 1.5 Simian virus 40 (SV40)………………………………………………… 17 1.5.1 SV40 large T antigen (SV40 LT)…………………………………….. 19 1.5.2 SV40 small t antigen (SV40 ST)……………………………………... 20 1.6 Specific aims……………………………………………………………. 22 Chapter 2. SV40 T/t-common polypeptide inhibits angiogenesis of human HER2-overexpressing cancer………………………….. 25 2.1 Aim of this study……………………………………………………….. 25 2.2 Materials and Methods………………………………………………… 26 2.2.1 Materials……………………………………………………………… 26 2.2.1.1 Chemical and reagent………………………………………………. 26 2.2.1.2 Reagent/Kit………………………………………………………… 29 2.2.1.3 Antibodies………………………………………………………….. 30 2.2.1.4 Others………………………………………………………………. 31 2.2.1.5 Cell lines and culture conditions…………………………………… 31 2.2.1.6 Recombinant adenovirus …………………………………………... 34 2.2.1.7 NOD/SCID mouse…………………………………………………. 35 2.2.2 Methods……………………………………………………………….. 35 2.2.2.1 Generation of recombination adenovirus…………………………... 35 2.2.2.2 Recombinant adenovirus plaques formation……………………….. 36 2.2.2.3 Screening of recombinant adenovirus clones………………………. 37 2.2.2.4 Upscaling the production of viral particles………………………… 37 2.2.2.5 Purification of recombinant adenovirus……………………………. 38 2.2.2.6 Viral particle titration………………………………………………. 39 2.2.2.7 Preparation of concentrated conditioned medium………………….. 40 2.2.2.8 MTT cell survival assay……………………………………………. 41 2.2.2.9 Endothelial cells transmigration assay……………………………... 41 2.2.2.10 Cancer cells transmigration assay………………………………… 42 2.2.2.11 Endothelail cells tube formation assay……………………………. 42 2.2.2.12 Total RNA isolation from cells…………………………………… 43 2.2.2.13 Reverse transcriptase polymerase chain reaction (RT-PCR)……… 43 2.2.2.14 Quantitative Real-Time PCR……………………………………... 45 2.2.2.15 Total protein isolation from cells…………………………………. 46 2.2.2.16 Western boltting…………………………………………………... 46 2.2.2.17 Enzyme-linked immunosobent assay (ELISA)…………………… 48 2.2.2.18 In vivo Matrigel plug assay and hemoglobin contents……………. 49 2.2.2.19 In vivo tumorigenesis assay……………………………………….. 50 2.2.2.20 Immunohistochemistry staining for evaluation of microvessel density……………………………………………………………... 50 2.2.2.21 In vivo Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay……………………………......... 51 2.2.2.22 Statistical analyses………………………………………………... 52 2.3 Results…………………………………………………………………... 52 2.3.1 Preparation of cancer cells concentrated conditioned medium (CM)... 52 2.3.2 Conditioned medium from rAd-T/t infected HER2-overexpressing ovarian cancer SK-OV-3 cells inhibits HMEC-1 migration…………. 53 2.3.3 Conditioned medium from rAd-T/t infected HER2-overexpressing ovarian cancer SK-OV-3 cells inhibited HMEC-1 tube formation….. 54 2.3.4 T/t-common inhibits tumor angiogenesis in HER2-overexpressing ovarian cancer SK-OV-3 cells………………………………………. 55 2.3.5 T/t-common inhibits the ability of HER2-overexpressing SK-OV-3 cancer cells to induce endothelial cell migration and tube formation through repressing HER2 expression………………………………… 56 2.3.6 T/t-common inhibits angiogeneic factors and induces antiangiogenic factors in HER2-overexpressing SK-OV-3 cancer cells……………... 57 2.3.7 T/t-common blocks ERK1/2 pathway mediates HER2 signaling-regulated HIF-1α and VEGF-A expression……………….. 57 2.3.8 T/t-common increases p38 mediates HER2 signaling-regulated TSP-1 expression…………………………………………………….. 59 2.3.9 T/t-common inhibits tumor angiogenesis and tumor growth in HER2-overexpressing ovarian cancer xenografts in NOD/SCID mice. 60 2.4 Discussion……………………………………………………………….. 60 Chapter 3. SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs cisplatin and doxorubicin……………………………………………………………….. 66 3.1 Aim of this study……………………………………………………….. 66 3.2 Materials and Methods………………………………………………… 67 3.2.1 Materials………………………………………………………………... 67 3.2.1.1 Cell lines and culture conditions…………………………………… 67 3.2.1.2 Recombinant Adenovirus…………………………………………... 70 3.2.1.3 Chemotherapeutic drugs…………………………………………… 70 3.2.1.4 NOD/SCID mouse…………………………………………………. 70 3.2.1.5 Antibodies………………………………………………………….. 71 3.2.2 Methods……………………………………………………………….. 71 3.2.2.1 Drug sensitivity analysis by MTT assay…………………………… 71 3.2.2.2 Flow cytometic detection of apoptosis…………………………….. 72 3.2.2.3 Western blotting……………………………………………………. 72 3.2.2.4 In vivo drug sensitivity assays……………………………………… 72 3.2.2.5 Statistical analyses…………………………………………………. 73 3.3 Results…………………………………………………………………... 73 3.3.1 SV40 T/t-common polypeptide specifically enhances chemosensitivity of HER2-overexpressing human cancer cells to chemotherapeutic drugs CDDP and DXR…………............................ 73 3.3.2 T/t-common enhances CDDP- or DXR-induced apoptosis in HER2-overexpressing human cancer cells …...................................... 74 3.3.3 T/t-common sensitizes the HER2-overexpressing cancer cells to chemotherapeutic agents through repressing HER2 expression……... 76 3.3.4 Modulation of apoptosis regulatory molecules by T/t-common in CDDP- or DXR-treated HER2-overexpressing cancer cells………… 77 3.3.5 Co-treatment with T/t-common enhances DXR’s inhibitory effect on HER2-overexpressing SK-OV-3.ip1 tumor in NOD/SCID mice…….. 78 3.4 Discussion……………………………………………………………….. 79 Chapter 4. Conslusion…………………………………………………………. 82 Figures and Tables…………………………………………………………….. 84 References……………………………………………………………………… 117 Appendix: Accompanying paper with this thesis | |
dc.language.iso | en | |
dc.title | 猴病毒40型T/t-common蛋白質在HER2大量表現癌細胞可抑制新生血管生成並增加化療藥物的毒殺能力 | zh_TW |
dc.title | SV40 T/t-common polypeptide inhibits angiogenesis and enhances the cytotoxic activity of chemotherapeutic agents in human HER2-overexpressing tumors | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳小梨,黃麗華,顧記華,黃敏銓 | |
dc.subject.keyword | HER2,猴病毒四十型T/t-common,血管新生,腫瘤生長,VEGF-A,TSP-1,cisplatin,doxorubicin,藥物感受性, | zh_TW |
dc.subject.keyword | HER2,SV40 T/t-common,angiogenesis,tumor growth,VEGF-A,TSP-1,cisplatin,doxorubicin,chemosensitivity, | en |
dc.relation.page | 135 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-11-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 5.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。